dorsaVi Quick Ratio
The Quick Ratio (Acid Test) of dorsaVi (DVL.AX) as of Jul 25, 2026 is 2.89. In the previous year, Quick Ratio (Acid Test) was 1.40 — a change of 106.43% (higher).
Get this data via API
Financial Data API
Quick Ratio
2.89
YoY
106.43%
Last updated:
Quick Ratio (Acid Test) of dorsaVi is 2026 2.89 . Quick Ratio (Acid Test) of dorsaVi was 2025 1.40 . It decreases by 106.43% higher compared to the previous year.
Access this data via the Eulerpool API
dorsaVi Stock analysis
What does dorsaVi do? The company dorsaVi Ltd is a leading company in the field of wearable technology based in Australia. The company was founded in 2000 by Andrew Ronchi, Andrew Dalziel, and Daniel Dorsch with the vision to improve people's health through the development of technologies that can measure human movement and performance.
dorsaVi's business model is based on the development and marketing of wearable technology for use in medicine, rehabilitation, and sports. The company aims to develop innovative, user-friendly, and reliable devices that help users optimize their movement and performance. The products are used by professional athletes, physiotherapists, trainers, and doctors worldwide.
dorsaVi's mission is to improve the health and well-being of people and prevent injuries by providing accurate and easy-to-use solutions. The company is built on three main pillars: Sports, Clinical, and Occupational. Each of these pillars has specific products and solutions to help users in different industries and application areas.
In the Sports field, dorsaVi offers a wide range of products and solutions for professional athletes and trainers to optimize their performance and prevent injuries. The company's flagship product is the ViPerform system. This system allows athletes to accurately analyze and improve their movements during training or competition. It consists of wireless sensors attached to various parts of the body to capture data on movements, speed, acceleration, and force. The data is then sent to the dorsaVi app in real-time, where it can be analyzed, visualized, and interpreted.
In the Clinical field, dorsaVi provides solutions for therapists and doctors to support patients in their recovery after an injury or surgery. The Sentral Clinical Movement Analysis System offered in this field is an advanced system for analyzing human movement. It allows therapists to observe and analyze movement patterns accurately to identify disruptions and weaknesses that may lead to pain or injuries. The collected data can help create individual therapy plans and accelerate recovery.
In the Occupational field, dorsaVi develops solutions for companies and employees to improve their health and safety in the workplace. This includes the Sentral Wearable Movement Monitoring System. The system is a wireless and non-invasive solution that allows employers and employees to record and analyze their movement and load profiles in real-time. The collected data can help make ergonomic adjustments in the workplace to prevent injuries and illnesses.
Over the years, dorsaVi has received numerous awards for its products and solutions. However, the company continues to strive to develop innovative technologies and products to help people optimize their movement and performance, increase their well-being, and maintain their long-term health. dorsaVi is one of the most popular companies on Eulerpool.
Frequently Asked Questions about dorsaVi stock
Quick Ratio (Acid Test) of dorsaVi is 2.89 in 2026.
Access this data via the Eulerpool API
Leverage — dorsaVi
All Key Metrics — dorsaVi
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth